The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II results of ivonescimab (AK112/ SMT112), a novel PD-1/VEGF bispecific, in combination with chemotherapy for first line treatment of advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGA) in EGFR/ALK.
 
Li Zhang
Consulting or Advisory Role - AstraZeneca; Innovent Biologics
Speakers' Bureau - AstraZeneca; BeiGene; HenRui; Innovent Biologics; Roche China
Research Funding - Akeso Biopharma (Inst); AstraZeneca (Inst); BMS (Inst); Chia Tai Tianqing Pharmaceutical Group (Inst); Junshi Pharmaceuticals (Inst); QiLu Pharmaceutical (Inst)
 
Wenfeng Fang
No Relationships to Disclose
 
Yuanyuan Zhao
No Relationships to Disclose
 
Yunpeng Yang
No Relationships to Disclose
 
Ningning Zhou
No Relationships to Disclose
 
Likun Chen
No Relationships to Disclose
 
Yan Huang
No Relationships to Disclose
 
Jianhua Chen
No Relationships to Disclose
 
Li Zhuang
No Relationships to Disclose
 
Yingying Du
No Relationships to Disclose
 
Wu Zhuang
No Relationships to Disclose
 
Qitao Yu
No Relationships to Disclose
 
Yanqiu Zhao
No Relationships to Disclose
 
Ming Zhou
No Relationships to Disclose
 
Weidong Zhang
No Relationships to Disclose
 
Yu Zhang
No Relationships to Disclose
 
Yixin Wan
No Relationships to Disclose
 
Weifeng Song
Employment - Akeso Biopharma
 
Yu Xia
Employment - Akeso Biopharma